Methylphenidate for the Treatment of PTSD With Associated Neurocognitive Complaints
NCT05776056
This study is recruiting at 3 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
Posttraumatic stress disorder (PTSD) is frequently accompanied by difficulty concentrating, poor memory, and inability to keep up with tasks, which negatively impacts a person's ability to function at work and in relationships. Currently available treatments do not fully relieve all symptoms. A published research report showed positive evidence that the stimulant medication methylphenidate was beneficial in treating these problems. This study will evaluate the ability of methylphenidate to treat PTSD and associated neurocognitive complaints in Veterans.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Posttraumatic Stress Disorder (PTSD)
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 4
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- VA Office of Research and Development
- Last updated on ClinicalTrials.gov
- August 19, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Alabama · 2
- Birmingham VA Medical Center, Birmingham, AL · Birmingham, AL
- Tuscaloosa VA Medical Center, Tuscaloosa, AL · Tuscaloosa, AL
Washington · 1
- VA Puget Sound Health Care System Seattle Division, Seattle, WA · Seattle, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.